Your browser doesn't support javascript.
loading
Curative efficacy of Yixin Bardiranjibuya Keli in treatment of somatoform disorders / 中国生化药物杂志
Article in Zh | WPRIM | ID: wpr-511786
Responsible library: WPRO
ABSTRACT
Objective To evaluate the clinical efficacy of Yixin Bardiranjibuya Keli combined with escitalopram in the treatment of somatoform disorders.Methods 90 patients with somatoform disorders from March 2014 to March 2015,were recruited in our hospital as the subjects of this study.According to the random number method,the observation group and the control group were divided into observation group(45 cases)and control group(45 cases).The control group was treated with escitalopram,and the observation group was treated with Yixin Bardiranjibuya Keli on the basis of the control group.(SCL-90),Hamilton Depression Rating Scale(HAMD),Hamilton Anxiety Scale(HAMA),Health Status Questionnaire(SF-36PCS),Mental Health Overall Evaluation(SF-36PCS)before and after treatment,MCS score,adverse reaction,and curative effect.Results After treatment,the scores of SCL-90,HAMD and HAMA in the observation group were significantly lower than those in the control group [(2.40±0.53)vs.(2.47±0.56),(7.32±1.08)vs.(13.69±2.81),(4.82±1.21)vs.(9.93±2.02)],respectively(P<0.05),and the scores of SF-36PCS and MCS were significantly higher than those of the control group(P<0.05).The total effective rate was 95.55(48.38±11.02)points(P<0.05),and the adverse reactions were significantly lower than those in the control group [8.88%(4/45)vs 24.44%(11/45)%,Significantly higher than the control group 73.33%(P<0.05).Conclusion Yixin Bardiranjibuya Keli combined with escitalopram for the treatment of somatosensory disorder is significant and effective in relieving anxiety and depression of the patients and improving the physical symptoms of the patients,which can be used as the first choice of treatment.
Key words
Full text: 1 Database: WPRIM Aspects: Patient_preference Language: Zh Journal: Chinese Journal of Biochemical Pharmaceutics Year: 2017 Document type: Article
Full text: 1 Database: WPRIM Aspects: Patient_preference Language: Zh Journal: Chinese Journal of Biochemical Pharmaceutics Year: 2017 Document type: Article